The rare capacity of heat shock protein-90 (Hsp90) to maintain the stability and functionality of almost all the components of cytoplasmic signaling networks was once viewed as a long-sought-after drug target to combat tumor resistance to single-molecule-based therapeutics, which still make up the vast majority of more than 1000 US food and drug administration (FDA)-approved cancer treatments today.1 This evidence concerns the gene HSP90AB1 and cancer.